Q1 EPS Estimate for Lexeo Therapeutics Increased by Analyst

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Investment analysts at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a report issued on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.78) per share for the quarter, up from their previous forecast of ($0.93). HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.66) EPS and FY2025 earnings at ($2.95) EPS.

LXEO has been the topic of a number of other research reports. Royal Bank of Canada cut their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday. Leerink Partners cut their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday, March 24th. Finally, Chardan Capital reissued a “buy” rating and set a $25.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $22.80.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ:LXEO opened at $4.10 on Friday. The stock has a market capitalization of $135.57 million, a P/E ratio of -1.30 and a beta of 3.85. Lexeo Therapeutics has a 52 week low of $2.32 and a 52 week high of $19.50. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $4.05 and a two-hundred day simple moving average of $6.58.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.09.

Hedge Funds Weigh In On Lexeo Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Allostery Investments LP acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at $33,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Lexeo Therapeutics in the fourth quarter valued at approximately $46,000. BNP Paribas Financial Markets grew its holdings in shares of Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in Lexeo Therapeutics during the 4th quarter worth approximately $69,000. Finally, SG Americas Securities LLC acquired a new stake in Lexeo Therapeutics during the 4th quarter worth approximately $72,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.